Thus, due to the critical interference of PDE5 with cGMP signaling, PDE5-induced cGMP targeting was proposed for the treatment of several biomedical conditions, including neurological disorders, PAH, hypertension, cardiomyopathy, cancer, ED, and lower urinary tract syndrome [27]. This evidence concerns the gene PDE5A and pulmonary arterial hypertension.